Date Title Description PDF
08 May 2024 On P&L The Company releases the press release related to the first three months of 2024 financial results Download
08 May 2024 On P&L The Company releases the first three months 2024 financial results presentation Download
25 Apr 2024 On business and financial situation ROVI announces agreement to manufacture pre-filled syringes Download
27 Feb 2024 On P&L The Company releases the press release related to the full year 2023 financial results. Download
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download

Pages

Date Title Description PDF
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download

Pages

Date Title Description PDF
27 Feb 2014 Informe anual de remuneraciones de consejeros 2013 Download
27 Nov 2013 Acuerdos estratégicos con terceros Download
26 Nov 2013 Acuerdos estratégicos con terceros Download
07 Nov 2013 Información sobre resultados (4) Download
07 Nov 2013 Información sobre resultados (3) Download

Pages